文献速递MDS 与骨髓增殖性肿瘤血栓与止血

真性红细胞增多症中白细胞计数升高与血栓事件之间的关联:REVEAL研究分析

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
PubMed 文献 · Blood · 2024-01-01

REVEAL前瞻性观察研究纳入2510例美国临床实践中的真性红细胞增多症(PV)患者,中位随访44.7个月,分析2271例中106例发生142次血栓事件。时间依赖Cox模型显示,血细胞比容>45%(HR 1.84)和白细胞计数>11×10^9/L(HR 2.35)与首次血栓事件显著相关;血细胞比容≤45%时白细胞>12×10^9/L仍显著相关(HR 1.95)。结果支持将白细胞计数纳入PV风险分层。

要点

  • REVEAL研究中,血细胞比容>45%与首次血栓事件显著相关(HR 1.84,95%CI 1.234-2.749,P=0.0028)。
  • 白细胞计数>11×10^9/L与首次血栓事件显著相关(HR 2.35,95%CI 1.598-3.465,P<0.0001)。
  • 血细胞比容控制在≤45%时,白细胞计数>12×10^9/L仍与血栓事件显著相关(HR 1.95,95%CI 1.066-3.554,P=0.0300)。

核心结论

  • 结果支持将白细胞计数纳入PV风险分层及治疗策略研究,并表明疾病管理中控制血细胞比容和白细胞计数均重要。

研究设计与样本

  • REVEAL为前瞻性观察研究,收集美国临床实践中2510例PV患者的前瞻性临床数据,中位随访44.7个月(范围2-59个月)。
  • 采用时间依赖协变量Cox比例风险模型,血液计数分别与性别、年龄、疾病病程、入组时血栓病史(基线协变量)及治疗(时间依赖协变量)共同建模。
  • 分析纳入2271例参与者,106例患者发生142次血栓事件。

主要发现

  • 研究期间首次血栓事件与血细胞比容>45%显著相关(HR 1.84,95%CI 1.234-2.749,P=0.0028)。
  • 研究期间首次血栓事件与白细胞计数>11×10^9/L显著相关(HR 2.35,95%CI 1.598-3.465,P<0.0001)。
  • 白细胞计数升高与首次血栓事件在低危和高危PV中均显著相关。
  • 血细胞比容控制在≤45%时,白细胞计数>12×10^9/L与血栓事件显著相关(HR 1.95,95%CI 1.066-3.554,P=0.0300)。

局限性

  • 原文指出白细胞计数升高与血栓事件的关联虽经回顾性研究提示,但该关系需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by clonal proliferation of hematopoietic progenitor cells and is associated with an increased risk of thrombotic events (TEs). Established risk factors for TEs in patients with PV include advanced age, TE history, and elevated hematocrit. Although an association of TE with elevated white blood cell (WBC) counts has been suggested by retrospective studies, this relationship needs further validation. The prospective observational study of patients with polycythemia vera in US clinical practices (REVEAL) study collected prospective clinical data from 2510 patients with PV with a median follow-up of 44.7 months (range, 2-59 months) from enrollment. Using time-dependent covariate Cox proportional hazards models, blood counts were individually modeled with sex, age, disease duration, TE history at enrollment (baseline covariates), and treatment (time-dependent covariate). Analysis of 2271 participants identified 142 TEs in 106 patients. Significant associations with initial TE occurrence during the study period were observed for hematocrit level >45% (hazard ratio [HR], 1.84; 95% confidence interval [95% CI], 1.234-2.749; P = .0028) and WBCs >11 × 109/L (HR, 2.35; 95% CI, 1.598-3.465; P < .0001). Elevated WBC count was significantly associated with initial TE occurrence in both low-risk and high-risk PV. When hematocrit was controlled at ≤45%, WBC count >12 × 109/L was significantly associated with TE occurrence (HR, 1.95; 95% CI, 1.066-3.554; P = .0300). The results support incorporation of WBC count into PV risk stratification and studies of treatment strategies, and indicate the importance of controlling both hematocrit and WBC count in disease management. This trial was registered at www.clinicaltrials.gov as #NCT02252159.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gerds AT, Mesa R, Burke JM, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024. PMID: 38142448. doi:10.1182/blood.2023020232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。